MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

24.06 0.25

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

23.64

Massimo

24.12

Metriche Chiave
By Trading Economics
Entrata	675K 53M
Vendite	1.8M 148M
P/E Media del settore	13.275 89.037
Margine di Profitto	35.57
Dipendenti	181
EBITDA	1.7M 80M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+41.73% upside

Dividendi
By Dow Jones
Utili prossimi	25 feb 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	166M 2.8B
Apertura precedente	23.81
Chiusura precedente	24.06

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 gen 2026, 23:07 UTC

Utili

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 gen 2026, 21:27 UTC

Utili

Texas Instruments 4Q Sales Rise, Profit Falls

27 gen 2026, 23:55 UTC

Discorsi di Mercato

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 gen 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 gen 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 gen 2026, 23:39 UTC

Discorsi di Mercato

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 gen 2026, 23:20 UTC

Utili

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 gen 2026, 23:20 UTC

Utili

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 gen 2026, 23:19 UTC

Utili

SK Innovation Posts Net Loss for Second Consecutive Year

27 gen 2026, 23:19 UTC

Utili

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 gen 2026, 23:18 UTC

Utili

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 gen 2026, 23:18 UTC

Utili

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 gen 2026, 23:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 gen 2026, 23:11 UTC

Discorsi di Mercato

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 gen 2026, 23:07 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 gen 2026, 22:17 UTC

Discorsi di Mercato

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 gen 2026, 22:06 UTC

Utili

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 gen 2026, 21:51 UTC

Utili

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

27 gen 2026, 21:43 UTC

Utili

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 gen 2026, 21:41 UTC

Utili

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 gen 2026, 21:38 UTC

Utili

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 gen 2026, 21:32 UTC

Utili

Ampol: Modest Profit From F&I International in 2025

27 gen 2026, 21:32 UTC

Utili

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 gen 2026, 21:31 UTC

Utili

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 gen 2026, 21:31 UTC

Utili

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 gen 2026, 21:30 UTC

Utili

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 gen 2026, 21:29 UTC

Utili

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 gen 2026, 21:29 UTC

Utili

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 gen 2026, 21:28 UTC

Utili

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

41.73% in crescita

Previsioni per 12 mesi

Media 34 USD 41.73%

Alto 35 USD

Basso 33 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.